The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, gives an overview of ongoing Phase III clinical trials evaluating ruxolitinib-based combinations in patients with myelofibrosis (MF). Prof. Kremyanskaya mentions the TRANSFORM-1 study (NCT04472598) which assesses the addition of navitoclax to ruxolitinib, as well as the MANIFEST-2 study (NCT04603495) testing the addition of pelabresib to ruxolitinib in treatment-naïve patients, and the LIMBER-313 (NCT04551066) and LIMBER-304 (NCT04551053) studies which are evaluating the addition of parsaclisib in newly diagnosed patients or patients who have a suboptimal response to ruxolitinib while receiving ruxolitinib monotherapy respectively. This interview took place virtually.
